(Q44153736)

30 November 2017

title

Interruption of combination antiretroviral therapy and risk of clinical disease progression to AIDS or death (English)

1 reference

30 November 2017

8

C Katlama

1 reference

30 November 2017

10

J D Lundgren

1 reference

30 November 2017

3

O Kirk

1 reference

30 November 2017

2

A Mocroft

1 reference

30 November 2017

11

EuroSIDA study group

1 reference

30 November 2017

C Holkmann Olsen

1

1 reference

30 November 2017

S Vella

4

1 reference

30 November 2017

A Blaxhult

5

1 reference

30 November 2017

N Clumeck

6

1 reference

30 November 2017

M Fisher

7

1 reference

30 November 2017

A N Phillips

9

1 reference

30 November 2017

publication date

1 March 2007

1 reference

30 November 2017

1 reference

30 November 2017

volume

8

1 reference

30 November 2017

issue

2

1 reference

30 November 2017

page(s)

96-104

1 reference

Time to discontinuation of the first highly active antiretroviral therapy regimen: a comparison between protease inhibitor- and non-nucleoside reverse transcriptase inhibitor-containing regimens

30 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2007.00436.X

Insights into the reasons for discontinuation of the first highly active antiretroviral therapy (HAART) regimen in a cohort of antiretroviral naïve patients. I.CO.N.A. Study Group. Italian Cohort of Antiretroviral-Naïve Patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2007.00436.X

Reasons for modification and discontinuation of antiretrovirals: results from a single treatment centre.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2007.00436.X

Patterns and correlates of discontinuation of the initial HAART regimen in an urban outpatient cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2007.00436.X

First-line therapy and mitochondrial damage: different nucleosides, different findings

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2007.00436.X

Adverse effects of antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2007.00436.X

Combination antiretroviral therapy and the risk of myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2007.00436.X

Accelerated bone mineral loss in HIV-infected patients receiving potent antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2007.00436.X

Effect of treatment interruption monitored by CD4 cell count on mitochondrial DNA content in HIV-infected patients: a prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2007.00436.X

Persistence of drug-resistant HIV-1 after a structured treatment interruption and its impact on treatment response

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2007.00436.X

Structured treatment interruption in patients with multidrug-resistant human immunodeficiency virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2007.00436.X

Structured treatment interruption in chronically HIV-1 infected patients after long-term viral suppression

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2007.00436.X

CD4+ count-guided interruption of antiretroviral treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2007.00436.X

Decline in the AIDS and death rates in the EuroSIDA study: an observational study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2007.00436.X

Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2007.00436.X

Substitution of nevirapine, efavirenz, or abacavir for protease inhibitors in patients with human immunodeficiency virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2007.00436.X

Low body weight and type of protease inhibitor predict discontinuation and treatment-limiting adverse drug reactions among HIV-infected patients starting a protease inhibitor regimen: consistent results from a randomized trial and an observational c

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2007.00436.X

Role of structured treatment interruption before a 5-drug salvage antiretroviral regimen: the Retrogene Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2007.00436.X

Reasons for Stopping Antiretrovirals Used in an Initial Highly Active Antiretroviral Regimen: Increased Incidence of Stopping due to Toxicity or Patient/Physician Choice in Patients with Hepatitis C Coinfection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2007.00436.X

10.1111/J.1468-1293.2007.00436.X

21 January 2018

Identifiers

DOI

1 reference

30 November 2017

1 reference